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IntroductIon
Hemophilia B is an X-linked recessive congenital bleeding disorder caused by the defi-
ciency of coagulation factor IX (FIX). This deficiency is invariably caused by mutations of F9 
gene, localized on the long arm of the chromosome X [1].
According to the data collected from 94% of the 54 Italian Hemophilia Treatment Centers 
and reported in the National Registry of Congenital Coagulopathies (NRCC) [2], in 2014 
in Italy the prevalence of hemophilia B was 1.4/100,000 inhabitants. Since hemophilia B is 
an X-linked disorder, it mainly affects male people (2.7/100,000 inhabitants) who represent 
98.5% of cases (n. = 809/821).
In hemophilia B, bleeding events can occur spontaneously, or following minor/major 
trauma or surgery, into joints (hemarthrosis), muscle (hematomas), or mucous membranes. 
Intracranial, neck/throat, and gastrointestinal bleeds are life threatening and require immedi-
ate treatment. The clinical manifestation of bleeding episodes relates to the severity of disease 
and depends on the circulating plasma levels of FIX [1] (Table I). According to NRCC data, 
in Italy severe, moderate and mild hemophilia B represent 35.7%, 21.7%, and 42.6% of all 
cases, respectively [2].
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AbstrAct
BACKGROUND: Enhanced pharmacokinetic profile of albutrepenonacog alfa allows to prolong the interdose period in 
prophylaxis, maintaining higher trough level, and to reduce dosage needed for bleeding. This improvement could lead to a 
better efficiency of the hemophilia B treatment.
OBJECTIVES: To estimate the impact of this new drug on the Italian National Health System (NHS).
METHODS: A model was developed from the NHS perspective to assess the budget impact of treating severe hemophilia 
B with reimbursed recombinant factor IX over 3 years in Italy. Target population was based on data from the National Reg-
istry of Congenital Coagulopathies, which collects data from 54 Hemophilia Treatment Centers. Treatment options were: 
albutrepenonacog alfa (Idelvion®), eftrenonacog alfa (Alprolix®) and nonacog alfa (BeneFIX®). Annual bleeding rate, dose 
and infusions needed to treat an episode based on clinical trials data were considered.
RESULTS: Mean costs per patient were calculated for prophylaxis and bleeding treatment by age groups. Applying age-
specific costs to the expected new pattern of drugs utilization, the impact on the NHS budget was € 6 million of savings 
cumulated in 3 years. The model results most sensitive to drug dosages. Lower drug consumption in prophylaxis and re-
duced bleeding rate than the alternatives reduce expenditures. Main limitations of this analysis were the assumptions that all 
severe patients receive prophylaxis and the lack of consideration of positive effects of hemorrhagic complications reduction 
(with consequent lower need of physiotherapy/prosthetic substitution).
CONCLUSIONS: The introduction of Idelvion® as therapeutic option for hemophilia B is expected to decrease pharmaceu-
tical costs and improve patient’s quality of life due to less frequent infusions. 
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Recurrent joint bleeding may lead to 
chronic arthropathy and progressive dam-
ages to the joint tissues that result in chronic 
pain, disabilities and poor quality of life. As 
reported in Kodra et al. [3] more than 75% of 
adult patients with hemophilia (A or B) have 
physical problems mainly related to mobility 
(75%) and pain/discomfort (76.7%), while 
both children and adults report a perceived 
reduction of quality of life of more than 25%. 
Hemophilia B is also associated with an high 
economic burden, since the mean annual total 
cost per patient estimated by Kodra et al. is equal to € 117,731.72, mainly represented by di-
rect health care costs (€ 109,768.70) of which 98% are imputable to drug costs [3].
Therapeutic strategies in the management of hemophilia B include replacement therapy 
with exogenous FIX concentrate for acute treatment of bleeding episodes (on-demand thera-
py) and prevention of bleeding episodes to preserve normal musculoskeletal functions (pro-
phylaxis therapy) [1]. Prophylaxis therapy is usually recommended for patients with severe 
hemophilia B who have the greatest risk of bleeding episodes, while in patients with mild and 
moderate disease on-demand treatment in case of acute bleed is indicated. As recommended 
by The Italian Association of Hemophilia Centres [4], in order to avoid spontaneous bleeding 
events, the aim of prophylaxis replacement therapy is to keep trough FIX level > 1-2 IU/dl, 
which usually requires intravenous infusion of FIX every 3 days. The need to administer FIX 
2 or 3 times per weeks and the difficulty to manage the injection, especially in children, may 
lead to an inconsistent treatment adherence, with a consequent increase of bleeding rate. FIX 
concentrates with longer half-life, which require fewer injections, may reduce the burden for 
the patient and improve adherence.
In Italy plasma-derived (pdFIX) and recombinant (rFIX) concentrates are available, with 
a prevalent consumption of rFIX, regardless of disease severity (82% in severe, 73% in 
moderate, and 94% in mild hemophilia B) [2]. Currently in Italy, three rFIX are available for 
treatment of hemophilia B: nonacog alfa (BeneFIX®, Pfizer S.r.l.), eftrenonacog alfa (Alpro-
lix®, Swedish Orphan Biovitrum S.r.l.) and albutrepenonacog alfa (Idelvion®, CSL Behring 
S.p.A.).
BeneFIX® (nonacog alfa) was the first rFIX to get marketing authorization in 1997. Ef-
ficacy and safety of two prophylaxis regimens (50 IU/kg twice weekly and 100 IU/kg once 
weekly) vs on-demand therapy were evaluated in a multicenter, randomized, open-label trial 
conducted on patients with moderately severe to severe hemophilia B (FIX:C ≤ 2%) [5]. Fif-
teen male subjects (age 6-65 years) with ≥ 12 bleeding episodes within 12 months of study 
participation were enrolled; the study included four periods: 1) a 16-week on-demand treat-
ment; 2) randomization and 16-week prophylactic treatment with BeneFIX® 50 IU/kg twice 
weekly or 100 IU/kg once weekly, 3) a 8-week on-demand treatment, 4) cross-over and 16 
weeks receiving the alternate study prophylactic regimen. The primary efficacy endpoint was 
the Annualized Bleeding Rate (ABR) of two prophylactic regimens vs on-demand therapy. 
Mean ABR values were 35.1, 2.6, and 4.6 for the first on-demand period, the 50 IU/kg twice 
weekly prophylaxis, and the 100 IU/kg once weekly prophylaxis, respectively. Both prophy-
laxis regimes had significantly reduced ABR compared to on-demand therapy (p < 0.0001), 
while no significant differences were observed between prophylaxis regimens (p = 0.22) [5]. 
In order to better assess the efficacy and safety of once-weekly prophylaxis with BeneFIX® 
compared with on-demand, 25 male patients (age 12-65 years) with moderately severe to 
severe hemophilia B (FIX:C ≤ 2%), ≥ 12 bleeding episodes in the previous 12-months and ≥ 
100 exposure days to FIX, were enrolled in a pivotal, multicenter, open-label trial [6]. Patients 
received on-demand therapy for 26 weeks followed by a 52-week prophylaxis period with 
100 IU/kg of BeneFIX®. Mean ABR (primary endpoint) was significantly lower during pro-
phylaxis period compared with on-demand (3.6 vs 32.9; p < 0.0001). The majority of bleeding 
events occurred (82.1%) responded to the first infusion.
Alprolix® is a recombinant rFIX fusion protein with a prolonged half-life that was devel-
oped to reduce the frequency between injections. Efficacy and safety of Alprolix® were evalu-
ated in a phase 3, non-randomized, open-label study which enrolled 123 male patients (≥ 12 
years) with severe hemophilia B (FIX:C ≤ 2%) [7]. Participants were assigned to one of four 
treatment groups which received: 1) weekly dose-adjusted prophylaxis (50 IU/kg to start), 2) 
interval-adjusted prophylaxis (100 IU/kg every 10 days to start), 3) on-demand treatment, 4) 
severity FIX level Bleeding episodes
Severe < 1 IU/dl (< 0.01 IU/ml) or 
< 1% of normal level
Spontaneous bleeding into 
joints or muscles
Moderate 1-5 IU/dl (0.01-0.05 IU/ml) 
or 1-5% of normal level
Occasional spontaneous 
bleeding. Prolonged bleeding 
with minor trauma or surgery
Mild 6-40 IU/dl (0.06-0.40 IU/ml) 
or 5-40% of normal level
Spontaneous bleeding is rare. 
Severe bleeding with major 
trauma or surgery
Table I. FIX level and severity of disease (normal level of FIX = 50-150 IU/dl or 
50-150%). Modified from [1]
3Farmeconomia. Health economics and therapeutic pathways 2018; 19(1)
L. Pradelli, S. Villa, G. Castaman
treatment in the perioperative period. Prophylactic treatments significantly reduced the ABR 
compared with on-demand, indeed ABR value were 3.0, 1.4, and 17.7 in groups 1, 2, and 3, 
respectively. The median weekly dose in group 1 was 45 IU/kg and the median dosing interval 
in the group 2 was 12.5 days. 90.4% of bleeding episodes occurred was resolved with one 
injection, the median dose per injection to resolve bleeding episodes was 46 IU/kg. Alprolix® 
was assessed in pediatric population in the kids B-LONG study, a phase 3, multicenter, open-
label trial conducted on 30 previously treated boys (age < 12 years) with hemophilia B (FIX:C 
≤ 2%) [8].
All participants received the first prophylactic dose (50-60 IU/kg weekly) which could be 
increased to a maximum of 100 IU/kg (adjustment to dose) and frequency of administration 
to a maximum of twice weekly (adjustment to dosing frequency). The median ABR was 2.0 
and 33% of patients reported no bleeding. The median average prophylactic dose was 58.6 
IU/kg per week [8].
In the clinical development program (PROLONG-9FP), which included previously treat-
ed adult and pediatric patients with severe hemophilia B (FIX ≤ 2%), Idelvion® demonstrated 
a favorable pharmacokinetics profile, which allows for a prolonged period between two doses 
in the prophylactic setting, maintaining an adequate FIX level, and fewer infusions at lower 
dose to stop bleeding per hemorrhagic episode [9-12]. This improvement could mean a reduc-
tion of costs associated with fewer infusions.
Purpose of this analysis is to estimate the impact of Idelvion®, a rFIX with prolonged FIX 
half-life, on the budget of the National Health System for the Italian population of patients 
with severe hemophilia B.
IdelvIon®
Idelvion® is a purified protein produced by recombinant DNA technology, generated by 
the genetic fusion of recombinant albumin to rFIX (rIX-FP). The cleavable linker that derives 
from the endogenous activation peptide in native FIX, remains intact until FIX is activated, 
after which it is released and made available for the coagulation process [13]. Idelvion® is in-
dicated for the treatment and prophylaxis of bleeding in all age groups of patients with hemo-
philia B [14]. In February 2010, Idelvion® has received orphan designation by the European 
Commission [15], which has been maintained [16] after the marketing authorization released 
on May 2016 [17], basing on the results of two pivotal studies conducted in adult/adolescent 
[11] and pediatric population [12].
PrOlOng study on adult/adolescent patients
The study of Santagostino et al. [11] is a prospective, non-randomized, multinational, 
open-label phase 3 study, designed to evaluate pharmacokinetics (PK), efficacy and safety 
of Idelvion® for prophylactic and on-demand treatment of previously treated patients (adult/
adolescent, age: 12-65 years) with severe or moderate hemophilia B (FIX ≤ 2 IU/dl).
All patients were included in a 14-day PK assessment period and received a single dose of 
Idelvion® (50 IU/kg). Patients were assigned to either prophylaxis treatment group (group 1) 
or on-demand treatment group (group 2). Patients in group 1 received Idelvion® (35-50 IU/kg, 
at investigator’s discretion) every 7 days for 26 weeks; thereafter, if they had no spontaneous 
bleeds for at least 4 weeks and were receiving ≤ 40 IU/kg or ≤ 50 IU/kg, they were allowed 
to switch to a dosing interval of 10 or 14 days, respectively, with 75 IU/kg and continued 
prophylaxis for the remaining treatment period.
Patients in group 2 received on-demand treatment (35-50 IU/kg) for 26 weeks followed 
by weekly prophylaxis (35-50 IU/kg) for additional 26 weeks or longer. The primary end-
points were the difference of the Annualized spontaneous Bleeding Rate (AsBR) between 
7-day prophylaxis and on-demand treatment period in group 2, and the safety of Idelvion® in 
terms of occurrence of inhibitors against FIX. The secondary endpoints included the ABR in 
all prophylaxis regimens and the number of injections required to achieve hemostasis when 
treating bleeding episodes.
The study enrolled 63 patients (40 in group 1 and 23 in group 2). Nineteen patients in the 
group 2 switched from on-demand treatment to weekly prophylaxis with a significant reduc-
tion of the median AsBR (15.43 vs 0.0; p < 0.0001). In group 1, after the first 26 weeks on 
weekly prophylaxis 28 patients (70%) switched to the 14-day (21 patients) or 10-day (7 pa-
tients) prophylaxis regimen at the dose of 75 IU/kg. No significant differences were observed 
in terms of ABRs between the 7- and 10/14-day regimens with a median of 0.0 spontaneous 
bleeds/year for all regimens. Results were similar for total and joint ABRs. A comparison be-
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PrOlOng extension study
This phase 3, open-label, multicenter, extension study was designed to investigate the 
long-term efficacy and safety of Idelvion® in patients who had completed the previously de-
scripted Santagostino and Kenet studies [19]. Treatment intervals could be extended to 10 or 
14 days with 50-75 IU/kg of Idelvion®, adult patients who were controlled on a 14-day regi-
men could switch to a 21-day regimen with 100 IU/kg of Idelvion®. The primary objective of 
the study is to evaluate the safety (in terms of occurrence of inhibitors against FIX); secondary 
endpoints include clinical efficacy and overall adverse events.
A total of 83 patients were enrolled (52 from [11], 24 from [12] and 7 who started prophy-
laxis following major surgery). In adult/adolescent population 45 (87%) patients ≥ 12 years 
switched from 7-day to 10- or 14-day regimen and 10 patients ≥ 18 years switched from 14- to 
21-day interval. In the pediatric population (< 12 years) 11 (46%) patients switched to 10- or 
14-day interval.
The interim results suggest the possibility to extend treatment intervals both in adult/ado-
lescent (AsBR during 21-day regimen = 0.0) and in children (AsBR during 10- and 14-day 
regimen = 0.0 and 1.16, respectively).
Methods
A budget impact model was adapted to simulate the economic impact of partially substi-
tuting Idelvion® for other rFIX for prophylactic treatment of patients with severe hemophilia 
B in Italy. The analysis is conducted from the perspective of the Italian National Health Sys-
tem over a 3-year period.
The economic impact is estimated by the analysis of total costs in a cohort of patients 
with severe hemophilia B eligible for prophylaxis with Idelvion® and comparing a scenario 
in which Idelvion® is not available (Scenario w/o Idelvion®) with a scenario following the 
introduction of Idelvion® (Scenario with Idelvion®) (Figure 1).
Population
Target population is defined based on 2014 data of NRCC [2], which collects epidemio-
logical and therapeutic data from 54 Hemophilia Treatment Centers and reports a total of 821 
patients with hemophilia B. Since hemophilia B mainly affects male people, for second and 
third year of analysis, the growth rate for the Italian male population is applied [20].
According to a conservative approach, only patients with severe disease are taken into 
account, therefore the estimated eligible population is calculated applying the percentage of 
patients with severe illness and identifying the subgroup of patients who receive rFIX, as 
reported in NRCC [2]. Patients flow resulted in 240, 242 and 243 patients for year 1, 2 and 3, 
respectively. Based on the Italian Hemophilia Registry data total target population is divided 
into pediatric (< 12 years) and adolescents/
adults population [21]. The calculation of the 
target population is reported in Table II.
Comparators and scenarios
Target patients are assigned to treatment 
with the rFIX products currently reimbursed 
in Italy: albutrepenonacog alfa (Idelvion®), 
eftrenonacog alfa (Alprolix®) and nonacog 
alfa (BeneFIX®). The comparison between 
current (Scenario w/o Idelvion®) and alter-
native (Scenario with Idelvion®) scenario 
derives from a simulation of prescribing sce-
narios. Table III shows the patient disposition 
according to the usage rate prevision of the 
different rFIX over the 3 years of analysis for 
the two scenarios considered.
Clinical inputs
All patients are assumed to be on a pro-
phylaxis regimen for the entire period of the 
simulation, therefore clinical inputs include 
the drug dosages used in prophylaxis and to Figure 1. Scheme of the budget impact analysis
Year 1 Year 2 Year 3
Pts with hemophilia B (n.) 821 826 831
Pts with severe hemophilia B (%) 35.7 35.7 35.7
Pts treated with rFIX (%) 82 82 82
Total target population 240 242 243
Pts ≥ 12 years (%) 86.4 86.4 86.4
Pts ≥ 12 years (n.) 208 209 210
Pts < 12 years (n.) 32 33 33
Table II. Calculation of the target population over the 3 years of analysis
 
 
scenario w/o Idelvion® (%) scenario with Idelvion® (%)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Idelvion® - - - 32.0 51.7 65.8
Alprolix® 32.6 49.1 62.8 16.9 23.6 30.4
BeneFIX® 67.4 50.9 37.2 51.1 24.7 3.8
Table III. Market share in current (w/o Idelvion®) and alternative (with Idelvion®) 
scenarios
tween the 7- and the 14-day regimens showed the non-inferiority of the longer dosing interval 
(mean AsBR difference: -0.79; CI95% = -1.780-0.197).
353 out of 358 (98.6%) bleeding episodes occurring during the study were successfully 
treated with 1 or 2 injections of Idelvion®. No life-threating bleeding episodes occurred.
The PK assessment showed mean FIX trough levels equal to 20 IU/dl (range 2.5-36.2 IU/
dl) and 12.4 IU/dl (range 3.1-25.4 IU/dl) at day 7 during once week prophylaxis with 40 IU/
kg and at day 14 during 14-day prophylaxis with 75 IU/kg, respectively. Finally, Idelvion® 
demonstrated a favorable safety profile with no serious adverse events observed and no pa-
tient who developed inhibitors to FIX or antidrug antibodies.
The results from this study demonstrate the safety and the efficacy of Idelvion® in adult/
adolescent patients and support the dosing interval up to 14 days during prophylaxis treatment 
since its ability to maintain FIX trough level above the commonly recommended target. These 
results are confirmed by the study of Zhang et al. [18] in which a population PK model was 
developed in order to simulate different dosing scenarios of Idelvion®. After a single intrave-
nous infusion of Idelvion® (25-75 IU/kg) the predicted median trough FIX level remained > 
5 UI/dl for up to 9.5, 12, and 16 days in adult/adolescent, children between 6-12 years, and 
children aged < 6 years, respectively. The median trough FIX levels were maintained > 5 IU/
dl for the duration of the dosing interval both for weekly regimens with 25, 35 and 40 IU/kg 
and with 75 IU/kg every 14 days in adolescent/adult patients, and for the weekly regimens 
with 35 and 49 IU/kg in children [18].
PrOlOng study on pediatric patients
The study of Kenet et al. [12] is a prospective, non-randomized, international, open-label, 
phase 3 study designed to evaluate efficacy, PK profile, and safety of Idelvion® in previously 
treated pediatric patients (< 12 years) with severe or moderate severe hemophilia B (FIX ≤ 2%).
All patients were included in a 14-day PK assessment period and received a single dose 
of Idelvion® (50 IU/dl). The patients then received weekly prophylaxis with Idelvion® at dose 
35-50 IU/kg (at investigator’s discretion) for up to 18 months. The primary objectives of the 
study were to evaluate the safety (in terms of occurrence of inhibitors against FIX) and the PK 
profile. The secondary endpoints included ABRs in the 7-day prophylactic regimen and the 
number of injections required to achieve hemostasis during a bleeding episode.
The study enrolled 27 pediatric patients. The comparison of the PK profile of Idelvion® 50 
IU/kg with previous FIX treatment showed a higher incremental recovery (< 6 years = 0.95 
vs 0.676 IU/dl per IU/kg; 6-11 years = 1.06 vs 0.793 IU/dl per IU/kg), a more than five-fold 
longer half-life (< 6 years = 89.6 vs 19.9 h; 6-11 years = 92.8 vs 17.7 h), slower clearance 
(< 6 years = 1.187 vs 7.158 ml/h/kg; 6-11 years = 1.059 vs 5.812 ml/h/kg) and greater area 
under the time-concentration curve (< 6 years = 4.583 vs 886 IU*h/dl; 6-11 years = 5,123 
vs 890 IU*h/dl). Patients maintained a median trough FIX level = 13.4 IU/dl during 7-day 
prophylaxis regimen.
The median total AsBR and ABR during the 7-day prophylaxis regimen were 0.0 and 
3.12, respectively, with no differences between the two age groups (AsBR = 0.0 in patients < 
6 years and 0.78 in patients 6-11 years; ABR = 2.64 in patients < 6 years and 3.39 in patients 
6-11 years). A total of 106 bleeding episodes 
occurred during the study (45 in patients < 
6 and 61 in patients 6-11 years) and 68.9% 
of them were traumatic. 94 (88.7%) and 9 
(8.5%) of these episodes were successfully 
treated with 1 or 2 injections, with a probabil-
ity of success (defined as the probability of 
achieving hemostasis with 1 or 2 injections) 
of 97.2% (CI95% = 92.0-99.0). Finally, Idel-
vion® demonstrated a favorable safety profile 
with no serious adverse events observed and 
no patient who developed inhibitors to FIX 
or antidrug antibodies.
The results from this study demonstrate 
the safety and efficacy of Idelvion® in the 
pediatric population and support the dos-
ing interval up to 7 days during prophylaxis 
treatment since it maintains FIX trough level 
above the commonly recommended target.
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PrOlOng extension study
This phase 3, open-label, multicenter, extension study was designed to investigate the 
long-term efficacy and safety of Idelvion® in patients who had completed the previously de-
scripted Santagostino and Kenet studies [19]. Treatment intervals could be extended to 10 or 
14 days with 50-75 IU/kg of Idelvion®, adult patients who were controlled on a 14-day regi-
men could switch to a 21-day regimen with 100 IU/kg of Idelvion®. The primary objective of 
the study is to evaluate the safety (in terms of occurrence of inhibitors against FIX); secondary 
endpoints include clinical efficacy and overall adverse events.
A total of 83 patients were enrolled (52 from [11], 24 from [12] and 7 who started prophy-
laxis following major surgery). In adult/adolescent population 45 (87%) patients ≥ 12 years 
switched from 7-day to 10- or 14-day regimen and 10 patients ≥ 18 years switched from 14- to 
21-day interval. In the pediatric population (< 12 years) 11 (46%) patients switched to 10- or 
14-day interval.
The interim results suggest the possibility to extend treatment intervals both in adult/ado-
lescent (AsBR during 21-day regimen = 0.0) and in children (AsBR during 10- and 14-day 
regimen = 0.0 and 1.16, respectively).
Methods
A budget impact model was adapted to simulate the economic impact of partially substi-
tuting Idelvion® for other rFIX for prophylactic treatment of patients with severe hemophilia 
B in Italy. The analysis is conducted from the perspective of the Italian National Health Sys-
tem over a 3-year period.
The economic impact is estimated by the analysis of total costs in a cohort of patients 
with severe hemophilia B eligible for prophylaxis with Idelvion® and comparing a scenario 
in which Idelvion® is not available (Scenario w/o Idelvion®) with a scenario following the 
introduction of Idelvion® (Scenario with Idelvion®) (Figure 1).
Population
Target population is defined based on 2014 data of NRCC [2], which collects epidemio-
logical and therapeutic data from 54 Hemophilia Treatment Centers and reports a total of 821 
patients with hemophilia B. Since hemophilia B mainly affects male people, for second and 
third year of analysis, the growth rate for the Italian male population is applied [20].
According to a conservative approach, only patients with severe disease are taken into 
account, therefore the estimated eligible population is calculated applying the percentage of 
patients with severe illness and identifying the subgroup of patients who receive rFIX, as 
reported in NRCC [2]. Patients flow resulted in 240, 242 and 243 patients for year 1, 2 and 3, 
respectively. Based on the Italian Hemophilia Registry data total target population is divided 
into pediatric (< 12 years) and adolescents/
adults population [21]. The calculation of the 
target population is reported in Table II.
Comparators and scenarios
Target patients are assigned to treatment 
with the rFIX products currently reimbursed 
in Italy: albutrepenonacog alfa (Idelvion®), 
eftrenonacog alfa (Alprolix®) and nonacog 
alfa (BeneFIX®). The comparison between 
current (Scenario w/o Idelvion®) and alter-
native (Scenario with Idelvion®) scenario 
derives from a simulation of prescribing sce-
narios. Table III shows the patient disposition 
according to the usage rate prevision of the 
different rFIX over the 3 years of analysis for 
the two scenarios considered.
Clinical inputs
All patients are assumed to be on a pro-
phylaxis regimen for the entire period of the 
simulation, therefore clinical inputs include 
the drug dosages used in prophylaxis and to Figure 1. Scheme of the budget impact analysis
Year 1 Year 2 Year 3
Pts with hemophilia B (n.) 821 826 831
Pts with severe hemophilia B (%) 35.7 35.7 35.7
Pts treated with rFIX (%) 82 82 82
Total target population 240 242 243
Pts ≥ 12 years (%) 86.4 86.4 86.4
Pts ≥ 12 years (n.) 208 209 210
Pts < 12 years (n.) 32 33 33
Table II. Calculation of the target population over the 3 years of analysis
 
 
scenario w/o Idelvion® (%) scenario with Idelvion® (%)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Idelvion® - - - 32.0 51.7 65.8
Alprolix® 32.6 49.1 62.8 16.9 23.6 30.4
BeneFIX® 67.4 50.9 37.2 51.1 24.7 3.8
Table III. Market share in current (w/o Idelvion®) and alternative (with Idelvion®) 
scenarios
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treat bleeding episodes. The choice of considering only prophylactic regimens is related to a 
series of considerations: prophylaxis represents the most followed regimen in severe hemo-
philia (about 70% according to the latest ISTISAN report [2]); it represents an event much 
greater share of total FIX expenditures, and it is anticipated that new Idelvion® patients will be 
predominantly treated with a prophylactic regimen, in order to benefit from its clinical feature 
of longer interdose intervals. The model considers the prophylaxis dosages to maintain FIX 
level ≥ 2% while the dose to treat a single episode is calculated based on the ABR, as reported 
in registration studies and/or in the scientific evaluation documents by the regulatory agencies 
EMA and FDA, and the Incremental Recovery (IR), defined as the increase of FIX per IU/kg 
administered. The dose estimation calculated based on IR has been preferred to the trial based 
usages as this is the practical approach used to determine the dose in the clinical setting. Table 
IV reports the clinical inputs used in the analysis.
Cost inputs
According to the study of Kodra et al. [3], in which drug costs account for 98% of all di-
rect health costs for hemophilia, the model considers only drug acquisition costs related to the 
prophylaxis treatment and the management 
of bleeding events. The consumption of each 
FIX is calculated taking into account an aver-
age weight of 25 kg for the pediatric popula-
tion (< 12 years), and of 70 kg for patients 
adolescents/adults (≥ 12 years).
According to NHS perspective, ex-facto-
ry prices per IU [22] are used for each prod-
uct (Table IV).
sensitivity analysis
Sensitivity analysis is provided by feed-
ing the model with alternative input sources 
to test the robustness of the results obtained 
and the parameters used in the base-case and 
to better understand the main drivers of the 
economic analysis.
 - Maximum dose of the drugs: the maxi-
mum dosages recommended in SPCs 
are tested for Idelvion® (< 12 years = 50 
IU/kg once a week; ≥ 12 years = 75 IU/
kg every 10 days) [14] and Alprolix® (< 
12 years = 60 IU/kg once a week; ≥ 12 
years = 100 IU/kg every 10 days) [23]. 
Due to the lack of data in SPC the dose to 
maintain the trough level > 5% (50 IU/kg 
three times a week [19]) are used for both 
adult and pediatric population treated 
with BeneFIX®.
 - Idelvion® market share: ±20% of Idelvi-
on® market share are tested.
results
Cost per patient
Figure 2 shows the mean annual pharma-
ceutical costs per patient affected by severe 
hemophilia B treated in prophylaxis with the 
three rFIXs currently available in Italy. Re-
sults are reported for prophylaxis and bleed-
ing treatment in the two age groups.
Budget impact
Table V shows the number of patients al-
located to the different treatment strategies in 
the two scenarios analyzed. 
The results of the budget impact analysis 
show that for an estimated target population 
eligible for treatment with rFIX of 240 pa-
tients for the first, 242 for the second, and 
243 for the third year, the economic impact 
of partially substituting Idelvion® for other 
rFIX for prophylactic treatment would result 
in a potential saving for the Italian NHS of € 
1,302,995, € 2,132,448, and € 2,725,789 in the course of the first, second and third year of 
treatment, respectively (Table VI). The cumulative budget impact for 3 years results in a total 
saving for the Italian NHS of € -6,161,232.
sensitivity analysis
Figure 3 shows the results of the scenario analysis.
 
Prophylaxis Bleeding episode ex-factory 
price (€/IU) 
[22]
Dose 
(IU/kg)
Infusion 
(n./week)
source ABr Ir
Dose 
(IU) 4
Infusion 
(n.)
source
Pts ≥ 12 years
Idelvion® 50 0.5 [18] 2,283 1.30 2,692 1.08 [5,11,14] 2.20
Alprolix® 50 1 [23] 3.07 0.92 3,804 1.123 [24-26] 1.38
BeneFIX® 40 2 [28] 2.60 0.80 4,375 1.27 [5,6,27] 0.69
Pts < 12 years
Idelvion® 47 0.861 [12] 3.78 1.00 1,250 1.14 [12,23] 2.20
Alprolix® 55 1 [23] 2.26 0.66 1,894 1.33 [8,24] 1.38
BeneFIX® 51.85 1.652 [28]2 3.90 0.56 2,232 1.275 [27] 0.69
Table IV. Clinical and cost inputs
1 Weighted average extrapolated from phase 3 extension study [19]
2 Mean value between 40 IU/kg twice a week indicated in adult population and 63.7 IU/kg every 3-7 days indicated in child < 6 years
3 Due to the lack of specific value, a mean value between BeneFIX® 50 IU/kg twice a week (ABR = 2.6 [5]) and Idelvion® 75 IU/kg every 14 days 
(ABR = 1.96 [23]) was assumed
4 Dose/infusion was calculated as: weigh (kg) x increase FIX/IR, where increase FIX is the FIX level required to stop bleeding (50% [29]).
5 Due to lack of specific value, according to a conservative approach, the same number of infusion was assumed both for adults and children
ABR = Annualized Bleeding Ratio; IR = Incremental Recovery
Figure 2. Mean annual pharmaceutical cost per patient
scenario with Idelvion® (n.) scenario w/o Idelvion® (n.)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Pts < 12 years
Idelvion® 0 0 0 10 17 22
Alprolix® 11 16 21 6 8 10
BeneFIX® 22 17 77 17 8 1
Pts ≥ 12 years
Idelvion® 0 0 0 66 108 128
Alprolix® 68 103 132 35 49 64
BeneFIX® 140 106 78 106 52 8
Table V. Distribution of patients between the different treatment strategies in both 
scenarios
 
Cost (€)
Year 1 Year 2 Year 3 Cumulated
scenario with Idelvion®
Idelvion® 15,609,287 25,372,344 32,487,546 73,469,177
Alprolix® 10,037,697 14,102,507 18,275,905 42,416,109
BeneFIX® 23,787,531 11,568,109 1,790,482 37,146,122
Total 49,434,514 51,042,960 52,553,933 153,031,407
scenario w/o Idelvion®
Idelvion® - - - -
Alprolix® 19,360,427 29,323,218 37,743,406 86,427,051
BeneFIX® 31,377,082 23,852,190 17,536,315 72,765,587
Total 50,737,509 53,175,408 55,279,722 159,192,639
Budget impact
- 1,302,995 - 2,132,448 - 2,725,789 - 6,161,232
Table VI. Results of the budget impact analysis over three years and cumulated
Figure 3. Results of the sensitivity analysis
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prophylaxis treatment and the management 
of bleeding events. The consumption of each 
FIX is calculated taking into account an aver-
age weight of 25 kg for the pediatric popula-
tion (< 12 years), and of 70 kg for patients 
adolescents/adults (≥ 12 years).
According to NHS perspective, ex-facto-
ry prices per IU [22] are used for each prod-
uct (Table IV).
sensitivity analysis
Sensitivity analysis is provided by feed-
ing the model with alternative input sources 
to test the robustness of the results obtained 
and the parameters used in the base-case and 
to better understand the main drivers of the 
economic analysis.
 - Maximum dose of the drugs: the maxi-
mum dosages recommended in SPCs 
are tested for Idelvion® (< 12 years = 50 
IU/kg once a week; ≥ 12 years = 75 IU/
kg every 10 days) [14] and Alprolix® (< 
12 years = 60 IU/kg once a week; ≥ 12 
years = 100 IU/kg every 10 days) [23]. 
Due to the lack of data in SPC the dose to 
maintain the trough level > 5% (50 IU/kg 
three times a week [19]) are used for both 
adult and pediatric population treated 
with BeneFIX®.
 - Idelvion® market share: ±20% of Idelvi-
on® market share are tested.
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dIscussIon
Hemophilia B is a rare bleeding disorder associated with high economic and societal bur-
den. On-demand therapy with pdFIX or rFIX concentrate is indicated for the acute treatment 
of bleeding episodes in the patients with mild and moderate disease. In patients with severe 
hemophilia B with high bleeding risk, a prophylaxis regimen is recommended in order to 
preserve normal musculoskeletal functions [1].
The enhanced PK profile shown by Idelvion®, a recombinant human coagulation FIX gen-
erated by the fusion with albumin, compared to existing FIX therapies, allows prolonged 
period between two doses in the prophylactic setting, maintaining an adequate FIX level, and 
fewer infusions at lower dose to stop bleeding per hemorrhagic episode [9-12,18,19]. The re-
sults from the pivotal studies [11,12] support the dosing interval up to 14 and 7 days in adult/
adolescent and pediatric population since both dosages demonstrated to keep trough FIX level 
> 1-2 IU/dl which is the commonly recommended target [4].
An important aspect related to the prophylaxis with FIX is the suboptimal adherence to 
the treatment due to the high number of infusion required. A poor adherence to FIX regimen, 
which may include dose-skipping and under-dosing, may lead to an increased bleeding rates 
and chronic pain. The prolonged period between injections could improve the adherence to 
the treatment and the clinical outcomes, while reducing total costs. In our economic analysis 
the mean cost per patient results lower for Idelvion® with respect to Alprolix® in the adult pop-
ulation, while among children Idelvion® is associated to slightly higher acquisition costs; the 
prophylaxis cost strongly drives pharmaceutical costs, representing about 91-95% of them. 
Under the hypothesis that Idelvion® gains 32%, 52% and 66% of the uptake, respectively at 
the end of the 1st, 2nd and 3rd year from the access, the model estimates for the Scenario with 
Idelvion® a total saving of 6.2 million Euros. From a resources reallocation point of view, this 
value means that 30 more patient-years could be covered without any expenditure increase. 
The result of sensitivity analysis shows a budget impact not significantly influenced by Idel-
vion® prevalence; instead, dose adjustment appears strongly associated to financial variations: 
in the hypothesis that Idelvion® at mean dose would be used in patients otherwise treated with 
BeneFIX® or Alprolix® at their maximum recommended doses, savings are maximized.
The main limitation of this analysis concerns the assumption that only, and all, severe 
patients receive prophylaxis; the model construction also ignores the positive effect of the 
better clinical outcomes on hemarthrosis onset with consequent minor need of physiotherapy/
prosthetic substitution, and related clinical and economic advantages.
conclusIons
The introduction of Idelvion® among the available therapeutic options against hemophilia 
B is expected to decrease pharmaceutical costs and to improve patient’s quality of life (less 
frequent infusions, higher trough levels, better protection against spontaneous bleeding), as 
compared with the other concentrates.
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